Translate cancer point mutations into personalized peptide microarrays
Each tumor exhibits an individual cancer mutation profile with shared and patient unique mutations. The resulting neoantigens can elicit strong immune responses with detectable antibody levels in patient sera.
The fingerprint analysis of antibody profiles to neoepitopes could precisely distinguish between immunogenic and non-immunogenic mutations, a prerequisite for high-precision cancer immunotherapy and cancer vaccine development. Antibody responses to neoepitopes could be compared in treatment responders and non-responders to search for predictive biomarkers. Furthermore, neoepitope response profiles could be a source to predict side effects to therapy.
- Validate therapeutic antibodies against tumor associated antigens
- Target Discovery: Identify immunogenic epitopes for immunotherapy
- Develop personalized cancer vaccines
- Monitor patient-specific anti-tumor antibody responses
- Discover prognostic cancer neoepitopes
PEPperPRINT GmbH provides custom neoepitope microarrays for cancer research. The PEPperCHIP® Cancer Neoepitope Microarrays cover up to 11,000 peptides for the personalized analysis of anti-tumor antibody responses are provided within 4 to 6 weeks.
- Microarray Content – cancer neoepitopes, sequencing data, custom peptide lists etc.
- Peptide Length– 15 amino acids by default (adjustable)
- Peptide Numbers – up to 5,500 different peptides printed in duplicate
- Control Peptides – HA and polio epitopes by default, optional custom controls
- Timeline – 4 weeks for microarray delivery, 2 weeks for data analysis & reporting
- Microarray Example – 2,750 wild type / neoepitope peptide pairs printed in duplicate
What our customer say
"We have rigorously tested the reproducibility, sensitivity, and specificity of peptide microarrays provided by the PEPperPRINT using biological samples and have published two papers. […] We found this platform to be extremely useful for our studies. These dedicated efforts are testament to the standard of excellence maintained by PEPperPRINT’s scientific staff, for continued improvement and innovation of peptide microarray technology."
Prof. David Han, UConn Health
Discovery of breast putative cancer antigens using an integrative platform of genomics-driven immunoproteomics. Qendro V, Lundgren DH, Palczewski S, Hegde P, Stevenson C, Perpetua L, Latifi A, Merriman J, Bugos G, Han DK. Proteomics 2017; doi: 10.1002/pmic.201600318 (Epub)
Integrative proteomics, genomics, and translational immunology approaches reveal mutated forms of Proteolipid Protein 1 (PLP1) and mutant-specific immune response in multiple sclerosis. Qendro V, Bugos GA, Lundgren DH, Glynn J, Han MH, Han DK. Proteomics 2017; 17(6); doi: 10.1002/pmic.201600322 (Epub)